ArticleJournal of innate immunity2026
Association of CD32-131H>R Polymorphism with End-Stage Chronic Obstructive Pulmonary Disease and Interstitial Lung Diseases.
Article in Journal of innate immunity, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionProgression to end-stage lung diseases is influenced by both environmental and genetic factors, yet predictive markers remain limited. The CD32-131H>R polymorphism in the FCGR2A gene alters the affinity of the FcγRIIa receptor for IgG and may impair immune clearance, potentially influencing immune responses involved in chronic lung disease. In our study, we investigated the association between the CD32-131H>R polymorphism and end-stage pulmonary diseases requiring LTX.
methodsThe CD32-131H>R polymorphism was determined in 985 lung transplant recipients and 2,116 matched controls via TaqMan genotyping assays.
resultsThe low-affinity CD32-131R allele was significantly more prevalent among lung transplant recipients with chronic obstructive pulmonary disease (COPD) and interstitial lung diseases (ILD) compared to controls (p < 0.0001 and p = 0.01, respectively).
conclusionOur study demonstrates that the CD32-131R allele is enriched among patients with end-stage COPD and ILD requiring LTX, highlighting a possible association between Fcγ receptor-mediated immune responses and end-stage pulmonary disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.